読み込み中
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
通常取引
$14.535
−$0.085 · -0.58%
日中の時刻はETです。市場データは遅延する場合があります。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日中レンジ
現在 $14.535
52週レンジ
現在 $14.535
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
77
割安
センチメント
64
強気
リスク
48
やや高いリスク
モメンタム
66
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日中レンジ
現在 $14.535
52週レンジ
現在 $14.535
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.64億 USD | 1.64億 USD | 118.9万 USD | — | — |
| 売上原価 | 1.73億 USD | 1.24億 USD | 1075.5万 USD | — | — |
| 粗利益 | 9031.8万 USD | 4007.5万 USD | −956.6万 USD | — | — |
| 研究開発 | 3億 USD | 2.82億 USD | 3.44億 USD | 2.95億 USD | 2.59億 USD |
| 販売・一般管理 | 1.52億 USD | 1.53億 USD | 1.07億 USD | 1.04億 USD | 8366.4万 USD |
| 営業費用 | 4.89億 USD | 4.35億 USD | 4.51億 USD | 3.99億 USD | 3.43億 USD |
| 受取利息 | 1030.7万 USD | 2027.3万 USD | 1304.3万 USD | 298.5万 USD | 45.1万 USD |
| 支払利息 | — | — | — | 298.5万 USD | — |
| 減価償却費と償却費 | 4732.4万 USD | 4360.6万 USD | 3312.7万 USD | 2113.5万 USD | 1398万 USD |
| 営業利益 | −3.98億 USD | −3.95億 USD | −4.61億 USD | −3.99億 USD | −3.43億 USD |
| 純利益 | −3.91億 USD | −3.72億 USD | −4.44億 USD | −3.96億 USD | −3.42億 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI1.62億1.64%98.74億 USD0.35%$151.22-1.66%
iShares Russell 2000 ETFIWM1.52億0.19%787.4億 USD0.19%$277.89-0.38%
Vanguard Morningstar Total Stock Market ETFVTI1.1億0.00%2.3兆 USD0.03%$381.2-0.20%
iShares Biotechnology ETFIBB4465.7万0.41%108.2億 USD0.44%$204.06-1.18%
Vanguard Morningstar Small-Cap ETFVB3984.98万0.02%1853億 USD0.03%$288.08-0.48%
Vanguard Extended Market ETFVXF3564.41万0.04%954億 USD0.05%$233.46-0.66%
Dimensional - US Small Cap ETFDFAS2836.6万0.08%338.69億 USD0.31%$78.24-0.14%
Schwab U.S. Small-Cap ETFSCHA2786.09万0.13%218.24億 USD0.03%$32.665-0.38%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
